Search clinical trials for: irinotecan, cetuximab, envafolimab

Total 4380 results

Beijing Hospital
Bethune Charitable Foundation

Recruiting

ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

Metastatic Colorectal Cancer | MSS | RAS Mutation

China
Sun Yat-sen University

Recruiting

Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer (CEIL)

Metastatic Colorectal Cancer

China
Anhui Provincial Cancer Hospital

Not yet recruiting

A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Stage III

China
Enzon Pharmaceuticals, Inc.

Unknown

A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma

Metastatic Colorectal Cancer

United States, Canada, Israel, Netherlands, United Kingdom
Fudan University

Not yet recruiting

Neoadjuvant Envafolimab in Resectable and Locally Advanced MSI-H/dMMR Rectal Cancer

Locally Advanced Rectal Carcinoma | MSI-High
The First Affiliated Hospital of Xiamen University

Active, not recruiting

Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC

Non-small Cell Lung Cancer Stage IV

China
Northern Jiangsu Province People's Hospital

Recruiting

A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer

NSCLC

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors

Solid Tumor

China
Eli Lilly and Company

Completed

Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors

Cancer | Refractory Solid Tumor

United States
Gruppo Oncologico del Nord-Ovest

Unknown

Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). (CRICKET)

Metastatic Colorectal Cancer

Italy
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer

Breast Cancer
Roswell Park Cancer Institute
Bristol-Myers Squibb

Terminated

Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan

Colorectal Cancer

United States
Peking Union Medical College Hospital

Not yet recruiting

Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients

Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC

Non-small Cell Lung Cancer
Hairong Liu

Not yet recruiting

Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma

Efficacy and Safety
Eli Lilly and Company

Completed

A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer

Colorectal Cancer | Colorectal Carcinoma | Colorectal Tumor

United States
Jiangsu Cancer Institute & Hospital

Not yet recruiting

RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2

Biliary Tract Cancer
Sun Yat-sen University

Recruiting

Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy

Metastatic Colorectal Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer

Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Johns Hopkins University; M.D. Anderson Cancer Center; University of Colorado... and other collaborators

Completed

External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas

Brain Cancer

United States, Canada
University of Alabama at Birmingham
National Cancer Institute (NCI)

Completed

Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer

Colorectal Cancer
Asan Medical Center

Completed

Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions

Advanced Colorectal Cancer

Korea, Republic of
National Cancer Center, Korea

Unknown

Preoperative Chemoradiotherapy With Cetuximab in Rectal Cancer (ERBIRIX)

Rectal Neoplasms | Neoadjuvant Treatment

Korea, Republic of
Joel Neal
Nektar Therapeutics

Completed

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

Tumors Metastatic to Brain | Stage IV Non-small Cell Lung Cancer (NSCLC) | Recurrent Non-small Cell Lung Cancer (NSCLC) | Extensive-stage Small Cell Lung Cancer (SCLC) | Recurrent Small Cell Lung Cancer (SCLC) | Metastatic Breast Cancer (mBC)

United States
Chipscreen Biosciences, Ltd.

Active, not recruiting

Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.

Non Small Cell Lung Cancer

China
New Mexico Cancer Care Alliance

Completed

Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer

Pancreatic Cancer

United States
Anhui Chest Hospital

Not yet recruiting

Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Phase I Trial of Envafolimab for Healthy Male Subjects

Healthy Male

China
Nektar Therapeutics

Completed

NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)

Colorectal Cancer | Tumor

United States
LaNova Medicines Limited

Suspended

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

Malignant Tumors

China
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy

Colorectal Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin

Gastric Cancer | Esophageal Cancer

United States
Ludwig-Maximilians - University of Munich
Sanofi; Merck Sharp & Dohme LLC; Pfizer; Hoffmann-La Roche

Completed

Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.

Metastatic Colorectal Cancer
Nektar Therapeutics

Completed

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Colorectal Cancer

United States, Belgium, Germany, India, Spain, United Kingdom
Shanghai Zhongshan Hospital

Recruiting

Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC

Colorectal Neoplasms Malignant

China
Fudan University

Not yet recruiting

Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC

Advanced Non-Small Cell Lung Cancer
GERCOR - Multidisciplinary Oncology Cooperative...
Hoffmann-La Roche

Active, not recruiting

Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (STRATEGIC-1)

Colorectal Cancer Metastatic

Ireland, France, Israel
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer

Esophageal Cancer

United States
Novartis Pharmaceuticals

Completed

A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Colorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, Colorectal

United States
Sir Run Run Shaw Hospital

Recruiting

Total Neoadjuvant Therapy With Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Ultra Low Rectal Adenocarcinoma (RECMULRA-TNT)

Rectal Cancer

China
Sir Run Run Shaw Hospital

Recruiting

Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma

Rectal Cancer

China
US Oncology Research
Bristol-Myers Squibb; Pfizer

Active, not recruiting

PhII ICb With/Without Erbitux in MBC Pts (CA225200)

Metastatic Breast Cancer

United States
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Advanced Endometrial Cancer

China
Fudan University

Recruiting

c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI

Colorectal Cancer

China
Gruppo Italiano per lo studio dei Carcinomi dell...

Completed

Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients (COMETS)

Metastatic Colorectal Cancer

Italy
Centre Hospitalier Universitaire Vaudois

Unknown

Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal Cancer

Colorectal Cancer

Switzerland
Sun Yat-sen University

Recruiting

Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.

Induction Chemotherapy | Locally Advanced Nasopharyngeal Carcinoma | PD-L1 | Envafolimab

China
Peking University People's Hospital
Peking University Shougang Hospital; Shandong Cancer Hospital and Institute

Recruiting

Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma

Ewing Sarcoma

China
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer
University College, London

Completed

Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer (EXCITE)

Rectal Cancer

United Kingdom

3

Subscribe